Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody, which is in Phase 2b clinical trial for the treatment of atopic dermatitis; ISB 1302, a HER2 X CD3 beat bispecific antibody that is in Phase 1/2 clinical trial for the treatment of metastatic HER2-positive breast cancer; and ISB 1342, a CD38 X CD3 beat bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma. The company's pre-clinical stage product pipeline comprises ISB 880 for the treatment of anti-inflammatory therapy; ISB 1908 and ISB 1909 T-cell engagers for the treatment of oncology; ISB 1442, an innate immune engager for the treatment of oncology; and GRC 39815, an inhibitor of the retinoid-related orphan receptor gamma for the treatment of chronic obstructive pulmonary disorder. It also offers Ryaltris nasal spray for allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals focuses on the development and manufacturing of high-quality branded and generic medicines for global markets. The company is engaged in creating centers of excellence in dermatology, oncology, and respiratory therapy.

msh id	COM:GLENMARKPHARMA
symbol	GLENMARK
name	Glenmark Pharmaceuticals Limited
homepage url	https://www.glenmarkpharma.com
country	IN
sector	Healthcare
industry	Drug Manufacturers - Specialty & Generic
market	STOCKS
employee count	15.56K
crunchbase url	-
linkedin url	-
founders	-

market cap	4.65B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.07
growth cost of revenue	0.02
growth depreciation and amortization	0.26
growth ebitda	0.04
growth ebitda ratio	-0
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-0.24
growth gross profit	0.06
growth gross profit ratio	0.02

COM:GLENMARKPHARMA

Glenmark Pharmaceuticals

Last Close

1,492.65

21/11 10:00

Market Cap

390.66B

Beta: -

Volume Today

421.23K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	1.24B
cost of revenue	1.24B
depreciation and amortization	58.29M
ebitda	298.62M
ebitda ratio	0.2
eps	0.4
eps diluted	0.4
operating expenses	703.53M
operating income	240.33M
operating income ratio	0.16

accounts receivables	-101.65M
capital expenditure	-72.79M
cash at beginning of period	168.93M
cash at end of period	172.82M
inventory	299.38M
working capital ttm	54.29B

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-